Topic:

Manufacturing

Latest Headlines

Latest Headlines

CRO Onyx signs up to help CRUK handle cancer R&D

Cancer Research UK has enlisted contract drugmaker Onyx Scientific to pitch in on some of its early research projects, handling development and manufacturing for clinical trials.

Catalent lends its weight to an armed-antibody cancer candidate

Drug developer Catalent is teaming up with biomarker outfit Minomic International to get a new prostate cancer treatment into the clinic, tapping its expertise in crafting targeted oncology treatments.

Recipharm buys into Italy with $165M CMO deal

Swedish contract developer Recipharm is looking to expand its share of the European manufacturing market, trading $164.5 million for Italy's Corvette Pharmaceutical Services.

AMRI swings to revenue growth amid a transitional year

Contract drug developer AMRI posted a 15% boost in its quarterly revenue, using M&A and manufacturing demand to help wean it off royalty cash.

Shire bails out a contractor to keep its drug on the market

Repeated regulatory woes for SCM Pharma have left the U.K. contract manufacturer unable to afford its necessary upgrades, forcing Shire, its largest customer, to step in and take over.

Almac pours $90M into N. Ireland, adding 350 jobs

Contract developer Almac has earmarked £54 million ($90 million) to expand in its native Northern Ireland, planning to add 348 jobs over 5 years.

Health Canada signs off on GSK's plans to improve its flu vaccine plant

GlaxoSmithKline has submitted its plans to whip its troubled Quebec flu vaccine plant into shape to Health Canada, and the regulator says the action outline is up to snuff.

Another CMO mishap stings Cubist

Cubist Pharmaceuticals is recalling 100 lots of its banner antibiotic Cubicin after problems with a contract manufacturer, its third such issue in 12 months.

Fluviral, FluLaval Tetra production on hold at Glaxo's troubled Quebec plant

GlaxoSmithKline is in the process of reviewing regulatory results from a June inspection that found that 10 areas of its Ste. Foy, Quebec, vaccine manufacturing plant needed improvements. But in the meantime, Health Canada has imposed a condition on the facility's license, requiring notice before Glaxo resumes production of Fluviral and FluLaval Tetra.

CMOs eye Russia for growth

Russia is striving to produce domestically 50% of the drugs sold in the country, and, to do so, it's encouraging global manufacturers to buy, build or rent facilities there.